From training medical students to helping surgeons perform operations using the latest tech, virtual reality (VR) is pushing the boundaries in medical care ever further, with the help of IEC Standards.
A collaboration between researchers at the University of Sheffield and Budapest Zoo sees an aging gorilla walk again with ease. Will this treatment be fruitful for humans?
Scientists at the university of sheffield.
Liesel, the elderly matriarch of the Budapest Zoo, had been struggling to walk on her left leg, signaling a possible battle with arthritis. This marked the initiation of a unique collaboration between veterinary expertise and cutting-edge science to alleviate the suffering of the aging primate.
Strategy using genetically engineered T cells would attack cancer while sparing healthy blood stem cells.
The research paper reviews the potential benefits of marine plasmalogens, a type of glycerophospholipid, in combating age-related diseases like Alzheimer’s and Parkinson’s. These compounds, abundant in marine resources, could improve lipid metabolism and reduce oxidative stress, offering a new avenue for improving the quality of life in aging populations.
Learn the difference between memory problems that can happen to all of us as we get older and real warning signs of dementia.
The complexity and rise of data in healthcare means that artificial intelligence (AI) will increasingly be applied within the field. Several types of AI are already being employed by payers and providers of care, and life sciences companies. The key categories of applications involve diagnosis and treatment recommendations, patient engagement and adherence, and administrative activities. Although there are many instances in which AI can perform healthcare tasks as well or better than humans, implementation factors will prevent large-scale automation of healthcare professional jobs for a considerable period. Ethical issues in the application of AI to healthcare are also discussed.
KEYWORDS: Artificial intelligence, clinical decision support, electronic health record systems.
Artificial intelligence (AI) and related technologies are increasingly prevalent in business and society, and are beginning to be applied to healthcare. These technologies have the potential to transform many aspects of patient care, as well as administrative processes within provider, payer and pharmaceutical organisations.
“It’s a time of huge uncertainty,” says Geoffrey Hinton from the living room of his home in London. “Nobody really knows what’s going to happen … I’m just sounding the alarm.”
In The Godfather in Conversation, the cognitive psychologist and computer scientist ‘known as the Godfather of AI’ explains why, after a lifetime spent developing a type of artificial intelligence known as deep learning, he is suddenly warning about existential threats to humanity.
Following more than seven years of research, researchers at the University of Seville-IBiS (Institute of Biomedicine of Seville) have identified a new key cell type with a critical role in the developmental processes of memory and learning. This breakthrough has been published in the prestigious journal Nature Neuroscience.
The research, led jointly by the University of Seville-IBiS and Karolinska Institutet, helps to understand how neural systems with decisive functions for human behavior mature. The in-depth study highlights the role of microglia, a group of cells that has been the subject of substantial information in recent years due to its involvement in various brain pathologies such as Alzheimer’s disease.
The drugmakers designed their updated vaccines to target the omicron subvariant XBB.1.5, which is slowly declining nationwide. But health experts and initial data suggest that the new shots will still be effective against Eris, or EG.5, and other widely circulating variants – all of which are descendants of omicron.
“I think that these vaccines will provide very substantial protection against EG.5. Maybe just a little bit of loss, but it’s nothing that I’m very concerned about,” Dr. Mark Mulligan, director of the NYU Langone Vaccine Center, told CNBC. “It looks like we’re going to be OK.”
All three companies are still waiting for the Food and Drug Administration to approve their vaccines, meaning those jabs won’t be available to the public for a month or so. The Centers for Disease Control and Prevention also has to decide which Americans should get the shots and how often.
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links:
At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.
